A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2014
At a glance
- Drugs GI 4000 (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- Sponsors GlobeImmune
- 28 Jan 2014 As per the Clinicaltrials.gov record, status changed from active, no longer recruiting to completed.
- 14 Sep 2011 Planned end date changed from 1 Dec 2010 to 1 Jul 2012 according to ClinicalTrials.gov.
- 01 Jun 2011 Results presented in ASCO-2011.